Abstract: The present invention relates to a method for diagnosing a respiratory tract infection in a subject, comprising determining in a sample from said subject the level of High-Mobility-Group-Protein B1 (HMGB1), and/or determining in a sample from said subject the level of a histone protein, and/or determining in a sample from said subject the level of Insulin-like growth factor binding protein, acid labile subunit (IGFALS), wherein the subject is diagnosed with a bacterial respiratory tract infection when the level of IGFALS is below a predetermined threshold level and/or the level of the histone protein is above a predetermined threshold value, and/or wherein the subject is diagnosed with a respiratory tract infection when the level of HMGB1 is above a predetermined threshold level.

Abstract: The present invention relates to diagnosis, prognosis, risk assessment, and/or risk stratification of an adverse event, particularly mortality, of a subject. The invention relates to a method that comprises determining a level of at least one histone, particularly histone H2B, H4, H2A and/or H3, in a sample of said subject, and wherein said level of at least one histone is indicative of said adverse event of said subject; and/or determining a level of proadrenomedullin (proADM) in a sample of said subject, and wherein said level of proADM is indicative of said adverse event of said subject. The invention further relates to kits for carrying out the methods of the invention.

Abstract: The present invention relates to the identification and use of diagnostic markers for ischemic stroke of the lacunar subtype. The invention relates to devices and kits for performing these methods.

Abstract: The present invention relates to the use of glial fibrillary acidic protein (GFAP) as a diagnostic marker for intracerebral hemorrhage. The invention especially relates to methods for the early detection of intracerebral hemorrhage. Such early and rapid detection can be performed rapidly e.g. by a test strip format assay. GFAP can be used as a stand-alone marker or in combination with one or more other markers.

Abstract: Provided are methods of diagnosing sepsis in a patient by detecting the presence and/or amount of at least two biomarkers of sepsis or severe sepsis/septic shock in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having sepsis or severe sepsis/septic shock or suspected of having sepsis or severe sepsis/septic shock, or to accurately diagnose a patient having, or suspected of having sepsis or severe sepsis/septic shock. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a sepsis therapy.

Abstract: The present invention relates to the identification and use of diagnostic markers for ischemic stroke of the lacunar subtype. The invention relates to devices and kits for performing these methods.

Abstract: Truncated terminal deoxynucleotidyl transferase (TdT) derivative from calf thymus, characterized in that the derivative in comparison to the native TdT is N-terminally truncated by up to 161 amino acids and has a 20- to 30-fold higher enzyme activity in solutions containing Co2+ ions, and its recombinant production and use.

Abstract: The present invention relates to methods of determining anti-infectious agent IgG avidity, for example, human anti-cytomegalovirus and human anti-toxoplasma IgG avidity, using a competitive assay format.

Abstract: The present invention relates to methods of determining anti-infectious agent IgG avidity, for example, human anti-cytomegalovirus and human anti-toxoplasma IgG avidity, using a competitive assay format.

Abstract: The present invention relates to the use of glial fibrillary acidic protein (GFAP) as a diagnostic marker for intracerebral hemorrhage. The invention especially relates to methods for the early detection of intracerebral hemorrhage. Such early and rapid detection can be performed rapidly e.g. by a test strip format assay. GFAP can be used as a stand-alone marker or in combination with one or more other markers.

Abstract: Truncated terminal deoxynucleotidyl transferase (TdT) derivative from calf thymus, characterized in that the derivative in comparison to the native TdT is N-terminally truncated by up to 161 amino acids and has a 20- to 30-fold higher enzyme activity in solutions containing Co2+ ions, and its recombinant production and use.